Opinion: Who benefits from classifying obesity as a disease?

Max Moser argues that classifying obesity as a disease has propelled the development of new pharmaceutical treatments, similar to the impact of antidepressants. This shift not only opens up potential new markets for pharmaceutical companies but also raises questions about the effectiveness and ethical implications of treating obesity this way. While it may offer hope for those struggling with weight management, it also risks oversimplifying the complex, multifactorial nature of obesity and could lead to over-reliance on medication without addressing underlying social and psychological issues.